Company profile: Phoenix Biotechnology
1.1 - Company Overview
Company description
- Provider of research and development of therapeutic agents and treatment regimens for cancer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phoenix Biotechnology
Ernexa
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ernexa company profile →
Tharimmune
HQ: United Kingdom
Website
- Description: Provider of development-stage therapeutics for cancer and chronic pruritus, including TH104, a transmucosal buccal film with nalmefene targeting µ- and kappa-opioid receptors and inhibiting IL-17 for pruritus in PBC and other conditions; TH3215, a bispecific HER2/HER3 antibody; and TH1940, an anti-PD-1 Picobody therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tharimmune company profile →
Pionyr
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics that enhance antitumor immunity by targeting the tumor microenvironment. Utilizes novel target discovery and antibody generation platforms and its Myeloid Tuning approach. Programs include PY314 (TREM2) to deplete tumor-associated macrophages, PY159 (TREM1) to repolarize them to counteract immunosuppression, and PY265 (MARCO) to activate immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pionyr company profile →
Immedica
HQ: Sweden
Website
- Description: Provider of niche/specialty care pharmaceutical products with commercial coverage across Europe and the Middle East. Portfolio includes Akynzeo for prevention of chemotherapy-induced nausea and vomiting; Ammonaps for urea cycle disorders; Arlevert for vertigo and tinnitus; Loargys for Arginase 1 Deficiency; Neofordex high-dose dexamethasone; and Nor-NOHA Blood Collection Tubes for blood collection and diagnostic purposes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immedica company profile →
Gloucester Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development, acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization; owned by Celgene. Its first compound, romidepsin, is a late-stage oncology drug candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gloucester Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phoenix Biotechnology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phoenix Biotechnology
2.2 - Growth funds investing in similar companies to Phoenix Biotechnology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phoenix Biotechnology
4.2 - Public trading comparable groups for Phoenix Biotechnology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →